Research Spotlight: Sinai Health System
Short-term insulin therapy successfully induces remission in Type 2 diabetes
A new study lead by researchers at Mount Sinai Hospital, part of Sinai Health System, has shown that early intervention with short-term intensive insulin therapy for four weeks can successfully induce a remission of Type 2 diabetes that lasts for up to one year thereafter.
The study was led by Dr. Ravi Retnakaran, an endocrinologist with Leadership Sinai Centre for Diabetes at Mount Sinai Hospital, and has just been published in BMJ Open Diabetes Research and Care. The findings of Dr. Retnakaran and his team show that the earlier that short-term intensive insulin therapy was administered after the diagnosis of diabetes, the more successful it was in sustaining a 48 week remission.
Dr. Ravi Retnakaran, endocrinologist with Leadership Sinai Centre for Diabetes at Mount Sinai Hospital
Short-term intensive insulin therapy is typically administered for a period of two to four weeks and can decrease insulin resistance, reduce glucagonemia, improve pancreatic beta-cell function and induce a remission that can last up to one year in just under 50% of patients. The study showed that those who had been diagnosed within the preceding two years and then undergone the treatment had the longest sustained remission. Patients who had sustained remission had better baseline beta-cell function that was preserved across the one year after stopping the treatment.
On the road to longer term remission
“This study points us in a very important direction in our quest to address one of the most prevalent chronic diseases today. The first point is the clear benefit of short-term intensive insulin therapy, and the second is the importance of early intervention within the first few years after diagnosis. Our quest is to better understand the factors that determine remission so that we can offer long term solutions for our patients. The current study tells us that one key factor is early intervention with short-term insulin therapy during a window of opportunity that only exists in the first few years after diagnosis,” said Dr. Retnakaran.
Home to world-class diabetes researchers and research centres
Dr. Retnakaran, an endocrinologist with Leadership Sinai Centre for Diabetes at Mount Sinai Hospital and an investigator with the Lunenfeld-Tanenbaum Research Institute, collaborated with Drs. Bernard Zinman and Caroline K. Kramer, both of Leadership Sinai Centre for Diabetes at Mount Sinai Hospital and Lunenfeld-Tanenbaum Research Institute, in conducting a major clinical trial known as RESET-IT that aims to induce remission of Type 2 diabetes. The institute ranks amongst the top diabetes research centres in the world.
More than three million Canadians have Type 2 diabetes and the World Health Organization recently warned that rates have quadrupled since 1980, with 422 million people worldwide living with diabetes. The rate is expected to double in the next 20 years.
Patients interested in participating in the RESET IT trial should contact: Ms. Haysook Choi at Mount Sinai Hospital at (416) 586-8778 or email@example.com.
Sinai Health System is one of Ontario’s 24 research hospitals that contribute to a healthier, wealthier, smarter province. Look for other RESEARCH SPOTLIGHT posts on our Healthier, Wealthier, Smarter blog or join the conversation about why health research matters for Ontario on Twitter, using the hashtag #onHWS.